Global Markets Direct is a cutting-edge provider of market research and business consultancies for a wide range of customers worldwide.
A team of analytics is capable to produce all sorts of market information and carry out extensive industry research using unique data and reliable sources to let customers know who they are at the market. Global Markets Direct has profound analytical experience in researching the industries and preparing customized reports across many specific fields.
The company is distinguished by its high-quality consulting products and close inspection of the issues under study. Diligent efforts of the experts make every piece of business information an exclusive source of feasible solutions and valuable advice.
With a commitment to serve every client need, Global Markets Direct collects and interprets the materials for the analysis, uses methods of primary and secondary research and develops one of a kind data packages for global clients. They are able to cover the tones of industry-related information to assist customers in taking the right business decisions and developing their strategic plans.
Under the supervision of skillful managers and experts, business analysts produce reports that include:
- Product portfolio
- Potentially strong market reviews
- Competitive analytics
- Prospect partners
- Mergers and acquisitions project data
- Latest trends across a particular industry area
- Research and development strategies
- The analysis of new customers
- A set of remedial measures for projects
They will search for new partners and highlight the current business issues plus develop new strategies and tactical steps to help you take the lead in the industry where you operate.
Publications found:
5,853
Sort by:
Gamma Secretase - Pipeline Review, H2 2020
US$ 3,500.00
Gamma Secretase - Pipeline Review, H2 2020 SUMMARY According to the recently published report 'Gamma Secretase - Pipeline Review, H2 2020'; Gamma Secretase (EC 3.4.23.) pipeline Target constitutes clo...
October 2020
83 pages
Growth/Differentiation Factor 8 - Pipeline Review, H2 2020
US$ 3,500.00
Growth/Differentiation Factor 8 - Pipeline Review, H2 2020 SUMMARY Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Myostatin also known as growth differentiation factor 8 or GDF-8 is a m...
October 2020
78 pages
Hepatitis C - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Hepatitis C (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis C and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
September 2020
426 pages
Psoriasis - Pipeline Review, H2 2020
US$ 2,500.00
... releases. The Psoriasis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Psoriasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
September 2020
956 pages
Polycystic Ovarian Syndrome - Pipeline Review, H2 2020
US$ 2,000.00
... . The Polycystic Ovarian Syndrome (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Polycystic Ovarian Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
September 2020
55 pages
Glaucoma - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Glaucoma (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Glaucoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
September 2020
385 pages
Celiac Disease - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Celiac Disease (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Celiac Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
September 2020
96 pages
Sinusitis - Pipeline Review, H2 2020
US$ 2,000.00
... Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Sinusitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
September 2020
120 pages
Thyroid Cancer - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Thyroid Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Thyroid Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
September 2020
1074 pages
Mild Cognitive Impairment - Pipeline Review, H2 2020
US$ 2,000.00
... . The Mild Cognitive Impairment (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Mild Cognitive Impairment and features dormant and discontinued projects. The guide covers therapeutics under Development ...
September 2020
121 pages
Oligodendroglioma - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Oligodendroglioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Oligodendroglioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
September 2020
175 pages
Depression - Pipeline Review, H2 2020
US$ 2,500.00
... . The Depression (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Depression and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
September 2020
737 pages
Pulmonary Arterial Hypertension - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
September 2020
412 pages
Herpes Zoster (Shingles) - Pipeline Review, H2 2020
US$ 2,000.00
... . The Herpes Zoster (Shingles) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Herpes Zoster (Shingles) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
September 2020
69 pages
Acromegaly - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Acromegaly (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Acromegaly and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
September 2020
96 pages
Chemotherapy Induced Anemia - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Chemotherapy Induced Anemia (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Anemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
September 2020
72 pages
Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Deep Vein Thrombosis (DVT) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Deep Vein Thrombosis (DVT) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
September 2020
35 pages
Dyskinesia - Pipeline Review, H2 2020
US$ 2,000.00
... . The Dyskinesia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
September 2020
262 pages
Friedreich Ataxia - Pipeline Review, H2 2020
US$ 2,000.00
... . The Friedreich Ataxia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Friedreich Ataxia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
September 2020
153 pages
Glomerulonephritis - Pipeline Review, H2 2020
US$ 2,000.00
... And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Glomerulonephritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
September 2020
322 pages
Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Keratoconjunctivitis Sicca (Dry Eye) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
September 2020
359 pages
Neutropenia - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Neutropenia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neutropenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
September 2020
137 pages
Opium (Opioid) Addiction - Pipeline Review, H2 2020
US$ 2,000.00
... . The Opium (Opioid) Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Opium (Opioid) Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development ...
September 2020
193 pages
Tetanus - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Tetanus (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tetanus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
September 2020
94 pages
Chlamydia Infections - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Chlamydia Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chlamydia Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
September 2020
88 pages
Fragile X Syndrome - Pipeline Review, H2 2020
US$ 2,000.00
... . The Fragile X Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fragile X Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
September 2020
194 pages
Hyperuricemia - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Hyperuricemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperuricemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
September 2020
86 pages
Pancreatic Cancer - Pipeline Review, H2 2020
US$ 2,500.00
... releases. The Pancreatic Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pancreatic Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
September 2020
4317 pages
Tinnitus - Pipeline Review, H2 2020
US$ 2,000.00
... Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Tinnitus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
September 2020
50 pages
Bacterial Conjunctivitis - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Bacterial Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Bacterial Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
September 2020
33 pages
Esophageal Cancer - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Esophageal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Esophageal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
September 2020
1584 pages
Malignant Mesothelioma - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Malignant Mesothelioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Malignant Mesothelioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
September 2020
1216 pages
Myocardial Infarction - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Myocardial Infarction (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Infarction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
September 2020
385 pages
Peritoneal Cancer - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Peritoneal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Peritoneal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
September 2020
1845 pages
Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Graft Versus Host Disease (GVHD) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Graft Versus Host Disease (GVHD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
September 2020
770 pages
Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
September 2020
162 pages
Gastric Ulcers - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Gastric Ulcers (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Gastric Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
September 2020
57 pages
Pancreatitis - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Pancreatitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Pancreatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
September 2020
106 pages
Premature Labor (Tocolysis) - Pipeline Review, H2 2020
US$ 2,000.00
... . The Premature Labor (Tocolysis) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Premature Labor (Tocolysis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
September 2020
53 pages
Rhabdomyosarcoma - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Rhabdomyosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Rhabdomyosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
September 2020
524 pages
Pyelonephritis - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Pyelonephritis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Pyelonephritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
September 2020
150 pages
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
September 2020
462 pages
Schistosomiasis - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Schistosomiasis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Schistosomiasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
September 2020
38 pages
Anesthetic Effect - Pipeline Review, H2 2020
US$ 2,000.00
... . The Anesthetic Effect (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Anesthetic Effect and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
September 2020
104 pages
Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Human Papillomavirus (HPV) Associated Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
September 2020
386 pages
Male Infertility - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Male Infertility (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Male Infertility and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
September 2020
38 pages
Retinopathy Of Prematurity - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Retinopathy Of Prematurity (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinopathy Of Prematurity and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
September 2020
68 pages
Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2020
US$ 2,000.00
... . The Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Proliferative Diabetic Retinopathy (PDR) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
September 2020
57 pages
